ARS Pharmaceuticals (SPRY) Long-Term Deferred Tax (2023 - 2025)

ARS Pharmaceuticals (SPRY) has 3 years of Long-Term Deferred Tax data on file, last reported at $73.4 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Deferred Tax rose 99.13% year-over-year to $73.4 million; the trailing twelve-month figure through Dec 2025 stood at $73.4 million (up 99.13% YoY), and the FY2025 full-year result was $73.4 million, up 99.13% from the prior year.
• Long-Term Deferred Tax climbed to $73.4 million in Q4 2025, from $36.9 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $73.4 million in Q4 2025 to a low of $29.0 million in Q4 2023.
• A 3-year average of $46.4 million and a median of $36.9 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax rose 26.92% in 2024 and soared 99.13% in 2025, its largest moves.
• Tracing SPRY's Long-Term Deferred Tax over 3 years: stood at $29.0 million in 2023, then increased by 26.92% to $36.9 million in 2024, then soared by 99.13% to $73.4 million in 2025.
• Business Quant data shows SPRY's Long-Term Deferred Tax at $73.4 million in Q4 2025, $36.9 million in Q4 2024, and $29.0 million in Q4 2023.